CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin

CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin

In this work, we examined the impact of polymorphism in the cytochrome P450 (CYP) 3A5 gene, CYP3A5*1 (6986A > G, rs 776746), on the reduction in the lipid levels caused by simvastatin and atorvastatin. We studied 350 hyperlipidemic patients who received 10-40 mg of atorvastatin (n = 175) or simva...

Full description

Bibliographic Details
Main Authors: Genovefa Kolovou, Vana Kolovou, Georgia Ragia, Constantinos Mihas, Olga Diakoumakou, Ioannis Vasiliadis, Sophie Mavrogeni, Vassiliki Vartela, Vangelis G Manolopoulos
Format: Article
Language:English
Published: Sociedade Brasileira de Genética 2015-06-01
Series:Genetics and Molecular Biology
Subjects:
atorvastatin
cholesterol
CYP3A5 gene polymorphism
simvastatin
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572015000200129&lng=en&tlng=en

Similar Items

Similar Items